Invasive lobular carcinoma (ILC) is treated with the same main tools as other breast cancers — surgery, radiation, and medicines that treat the whole body — but the way it grows shapes how doctors plan. Instead of forming one solid lump, lobular cancer cells tend to spread out in single-file lines through the breast tissue. That growth pattern can make the true size of the cancer harder to feel and harder to measure on imaging, so planning often pays extra attention to mapping the cancer before surgery and checking margins carefully afterwards.
Key Takeaways
- ILC cells grow in lines rather than a lump, so the cancer can be larger or more spread out than it first appears on examination or imaging.
- Treatment plans are built from the same information used for any breast cancer: stage, grade, hormone receptor status, HER2 status, your overall health, and your preferences.
- Surgery planning gets special care with ILC: doctors work to remove the cancer with a clear margin of healthy tissue, and imaging such as MRI is sometimes used beforehand to map the extent.
- ILC is very often hormone-receptor positive, so hormone therapy is commonly part of the plan. Chemotherapy decisions depend on the stage and features of each individual cancer.
- Because lobular cancer can occasionally appear in both breasts, doctors usually image and monitor the other breast carefully too.
How the Growth Pattern Shapes Planning
Most breast cancers begin in the milk ducts; lobular carcinoma begins in the lobules, the glands that make milk. Its cells lack a protein that normally helps cells stick together, so instead of clumping into a ball, they infiltrate the tissue in strands. Our explainer on invasive lobular carcinoma covers the biology in plain language, and our comparison of invasive ductal vs invasive lobular carcinoma sets out the differences side by side.
For treatment planning, this growth pattern has three practical effects. First, there may be no lump to feel, and a mammogram can underestimate how much tissue is involved. Second, the cancer can occasionally be present in more than one area of the same breast, or in both breasts. Third, surgeons plan carefully to remove the whole affected area with a rim — a “margin” — of normal tissue around it, and the pathology report on margins guides whether anything more is needed. None of this makes ILC untreatable; it simply means the mapping stage of planning is especially important. The overall framework doctors use is described in our pillar guide on how breast cancer treatment plans are made.
The Information Doctors Use
Before recommending a plan, your team pulls together a standard set of facts:
| Factor | Why it matters for ILC |
|---|---|
| Stage (size and spread) | Sets the overall scale of treatment — whether the cancer is confined to the breast, involves lymph nodes, or has spread further. |
| Grade | Describes how abnormal the cells look and how quickly they are likely to grow. |
| Hormone receptors (ER/PR) | ILC is usually hormone-receptor positive, which makes hormone-blocking treatment useful. Your pathology report will confirm your own result. |
| HER2 status | If the cancer is HER2-positive, HER2-targeted medicines may be part of the plan. |
| Imaging of both breasts | Helps map the extent of the cancer and check the other breast, since lobular cancer can be harder to see and can occur on both sides. |
| Your health and preferences | Other medical conditions, medicines you take, and what matters to you all shape the final plan. |
Sometimes a gene-expression test on the tumor tissue is also used to help estimate the benefit of chemotherapy in early-stage, hormone-receptor-positive cancers. Your team will explain whether such a test is appropriate in your case.
Surgery Decisions
Surgery is usually the first main step for early-stage ILC, and it takes one of two forms: breast-conserving surgery (lumpectomy), which removes the cancer with a margin of tissue, or mastectomy, which removes the whole breast. Our guide to comparing lumpectomy and mastectomy explains how patients and surgeons weigh the two.
With ILC, the discussion often includes a few specific points. Because the borders of the cancer can be hard to define, the surgeon may use imaging studies — sometimes including breast MRI — to plan exactly what to remove. If the pathology report shows cancer cells at the edge of the removed tissue (a “positive margin”), a second, smaller operation to take more tissue is sometimes recommended. For some patients, the extent of disease found on imaging makes mastectomy the more practical option from the start. Lymph nodes under the arm are usually sampled at the same operation to check whether the cancer has spread there, which feeds into decisions about radiation and medicines. If mastectomy is chosen, reconstruction options can be discussed with the surgical team.
Radiation Therapy
Radiation is commonly recommended after breast-conserving surgery, to lower the chance of the cancer coming back in that breast. After mastectomy, it depends on features such as the size of the cancer and whether lymph nodes were involved. Your team will explain whether radiation fits your situation and what a course of treatment involves day to day. The National Cancer Institute’s treatment overviews at cancer.gov are a reliable place to read more about each treatment type.
Whole-Body (Systemic) Treatments
Medicines that travel through the whole body are used to reduce the risk of the cancer returning elsewhere. Which ones are recommended depends on the stage and biology of your individual cancer — this is general information, not a recommendation for any person:
- Hormone therapy. Because ILC is very often hormone-receptor positive, hormone-blocking treatment is a central part of many plans, given for a period of years. The specific medicine and length of treatment are decisions for you and your oncologist, based on your pathology and circumstances.
- Chemotherapy. Whether chemotherapy is likely to help depends on factors such as tumor size, lymph node involvement, grade, and sometimes the results of a gene-expression test. It may be given before surgery in some situations — for example, to shrink a larger cancer — or afterwards.
- Targeted therapy. If the cancer is HER2-positive, medicines that target HER2 may be added. Other targeted medicines are sometimes used in specific situations your oncologist would explain.
The approach for the more common ductal type is set out in our guide to how doctors approach invasive ductal carcinoma treatment — the toolbox is the same; it is the growth pattern and hormone profile that most often change the emphasis with ILC.
Follow-Up and the Other Breast
After treatment, follow-up usually includes regular examinations and scheduled mammograms of any remaining breast tissue. Because lobular cancer has a somewhat higher chance than other types of appearing in the opposite breast, doctors keep a careful watch on both sides, and some patients discuss additional imaging with their team. Hormone-receptor-positive cancers can also return many years later, which is one reason long-term follow-up and completing the full course of any hormone therapy matter. If anything new appears — a change in either breast, or new persistent symptoms elsewhere — report it rather than waiting for the next scheduled visit.
Questions to Ask Your Doctor
- What is the stage and grade of my cancer, and what are its hormone receptor and HER2 results?
- How large does the cancer appear to be, and would MRI or other imaging help map it before surgery?
- Am I a candidate for breast-conserving surgery, or is mastectomy more advisable in my case — and why?
- What happens if the margins are not clear after surgery?
- Will I need radiation? Chemotherapy? Hormone therapy — and for how long?
- How will the other breast be monitored?
- What follow-up schedule do you recommend once treatment ends?
Frequently Asked Questions
Is lobular cancer treated completely differently from ductal cancer?
No. The same treatments are used, and the same factors drive the plan. The main differences are practical: extra care mapping the cancer’s extent before surgery, close attention to margins, and the fact that hormone therapy is relevant for most patients because ILC is usually hormone-receptor positive.
Does ILC always require a mastectomy?
No. Many patients have breast-conserving surgery successfully. Mastectomy is more likely to be discussed when imaging shows a large area of involvement or cancer in several areas of the breast, but it is not automatic, and the decision is individual.
Why might my doctor suggest an MRI before surgery?
Because ILC can be hard to measure with a mammogram alone, MRI sometimes gives a clearer picture of how much of the breast is involved and whether the other breast is affected. That helps the surgeon plan an operation that removes the cancer completely the first time.
Why is hormone therapy mentioned so often with ILC?
Most lobular cancers grow in response to hormones, which means blocking those hormones is an effective way to lower the risk of recurrence. Your pathology report shows whether your cancer is hormone-receptor positive, and your oncologist will discuss whether hormone therapy fits your plan.
Can ILC come back many years later?
Hormone-receptor-positive breast cancers in general can recur later than some other types, sometimes years after treatment. This is why completing recommended hormone therapy and keeping follow-up appointments long-term are important. Your team will outline the follow-up schedule they advise for you.
Related Articles
- How Breast Cancer Treatment Plans Are Made: A Plain-Language Guide
- Invasive Lobular Carcinoma Explained
- Invasive Ductal vs Invasive Lobular Carcinoma: The Key Differences
- How Doctors Generally Approach Treatment for Invasive Ductal Carcinoma
- Lumpectomy and Mastectomy: How to Compare Your Options
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.